Novavax (NASDAQ:NVAX), a leading player in the biopharmaceutical industry, has seen increasing institutional interest in ...

Dynavax Technologies (NASDAQ:DVAX) saw increased institutional activity as it advances vaccine initiatives like HEPLISAV-B.

Shares of Novavax Inc. NVAX shed 2.37% to $6.19 Tuesday, on what proved to be an all-around mixed trading session for the ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Shares of Novavax Inc. NVAX rallied 6.11% to $6.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 4.35% to ...

Shares of pharmaceutical companies declined after U.S. President Donald Trump announced plans to lower U.S. prescription drug ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax, Inc. (NASDAQ:NVAX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. Consensus estimates suggest investors could expect ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Lyft releases its first-quarter results after Thursday's closing bell. Here's a look at the details of the report.

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...